About: Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 21 March 2012

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2012 (uk) im März 2012 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 21 March 2012 (en) artículu científicu espublizáu en marzu de 2012 (ast)
publication date	wds:Q83720294-6592EA64-2702-46DF-889A-6BBFF1D386B1
publication date	2012-03-21 00:00:00Z (xsd:dateTime)
author name string	wds:Q83720294-250D82F6-409C-401F-B1C3-6429630CE562 wds:Q83720294-266BE17C-053C-4862-9B25-BD19930CE00B wds:Q83720294-27D4825B-A53A-4BCC-835D-F95CB9601EE4 wds:Q83720294-66892502-940B-4BC8-AB01-B82E35F66C62 wds:Q83720294-895DA91D-22B6-4F3B-8AA6-76798F36A3C9 wds:Q83720294-9724AA17-401A-4EF0-ACD1-0070B4F99AD6 wds:Q83720294-A81A5CDD-9508-44DF-9A2D-CED9DD148D9A wds:Q83720294-BA93BE0A-1072-4389-B8CB-C29EDA0D4C64 wds:Q83720294-D39C406E-AB29-403E-97D1-8C042C8C5451 wds:Q83720294-EC1AF589-E970-4F0D-9C84-1E53E6546383
author name string	Daniel Gaudet Harald Petry Diane Brisson André C Carpentier Sébastien M Labbé Jaap Twisk René Gagnon Frédérique Frisch Janneke de Wal Stephen Greentree
rdfs:label	Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients (en) Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients (nl)
skos:prefLabel	Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients (en) Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients (nl)
name	Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients (en) Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients (nl)
title	wds:Q83720294-DAB7C452-5F5A-48E0-9BC8-788F48715FD1
title	Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients (en)
page(s)	wds:Q83720294-A63EE330-3FB9-4D97-BED1-DAF9FF92E8A7
page(s)	1635-1644
instance of	wds:Q83720294-9CBF71EA-D9B0-4F7C-81CF-8C8CDA79C992
instance of	scholarly article
PubMed ID	wds:Q83720294-6E1A9D0D-7559-448F-B512-004C84AB5A9A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22438229
PubMed ID	22438229
published in	wds:Q83720294-67BC4BBF-7B85-4BA5-A9F6-72E88B117D0A
published in	The Journal of Clinical Endocrinology and Metabolism
issue	wds:Q83720294-A3023D4D-8C73-4C0A-920A-7973E8126A15
volume	wds:Q83720294-8E4A6FE4-C2E8-4AE8-BC5F-2F720A32FA62
issue	5
volume	97
DOI	wds:Q83720294-B426BAA8-9C6D-4A91-A0D4-E098688395FB
DOI	http://dx.doi.org/10.1210/JC.2011-3002
DOI	10.1210/JC.2011-3002
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q83720294
is cites work of	Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications Lessons learned from the clinical development and market authorization of Glybera. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates A largely random AAV integration profile after LPLD gene therapy Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement Adeno-associated Virus as a Mammalian DNA Vector Engineering adeno-associated viruses for clinical gene therapy Immune responses to AAV vectors: overcoming barriers to successful gene therapy Gene therapy enters the pharma market: the short story of a long journey Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome Adeno-associated virus (AAV) vectors in cancer gene therapy. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of AAV Serotypes 4, 5, and 11. Chylomicronaemia--current diagnosis and future therapies An alternate route for adeno-associated virus entry independent of AAVR. The SUMOylation Pathway Restricts Gene Transduction by Adeno-Associated Viruses Unraveling the complex story of immune responses to AAV vectors trial after trial Moving forward toward a cure for hemophilia B. AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases Concise Review: The Potential Use of Intestinal Stem Cells to Treat Patients with Intestinal Failure Cardiovascular Gene Therapy: Past, Present, and Future Adeno-Associated Viral Vectors in Neuroscience Research Quantile-dependent expressivity of postprandial lipemia Centronuclear myopathies under attack: A plethora of therapeutic targets In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? AAV shuffles to the liver: commentary on Lisowski et al. Oligonucleotide conjugated multi-functional adeno-associated viruses. Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat Utilization New trends in articular cartilage repair Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application Angiotensin 1-7 Overexpression Mediated by a Capsid-optimized AAV8 Vector Leads to Significant Growth Inhibition of Hepatocellular Carcinoma In vivo. Next-generation muscle-directed gene therapy by in silico vector design An engineered serum albumin-binding AAV9 capsid achieves improved liver transduction after intravenous delivery in mice Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing Regulatory Oversight of Cell and Gene Therapy Products in Canada [Severe hypertriglyceridemia : Diagnostics and new treatment principles].
is cites work of	wds:Q34311144-FA171876-F04D-4B00-9F7E-438031B1E1C8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software